Listing Regulation

• Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851

  21 November 2025

• Kancera AB changes name to Novakand Pharma AB

  22 September 2025

• Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851

  28 August 2025

• Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

  23 May 2025

• Kancera changes Certified Adviser to Redeye AB

  14 March 2025

• Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

  21 February 2025

• Interim Report Third Quarter 2024, July 1 – September 30 Kancera AB (publ.), org.no. 556806-8851

  15 November 2024

• Interim Report Second Quarter 2024, April 1 – June 30, Kancera AB (publ.), org.no. 556806-8851

  23 August 2024

• Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

  17 May 2024

• Kancera announces the outcome of the company’s rights issue

  20 March 2024